Highlights
- Major U.S. Expansion: Pro Medicus signs a 7-year, AU$40 million deal with LucidHealth to implement its Visage 7 platform.
- Cloud-Based Rollout: The platform rollout begins immediately, with a phased ‘go live’ starting in Q3 2025.
- Strategic Growth Opportunity: LucidHealth, with over 300 radiologists across 140 care sites, becomes a key client for Pro Medicus.
Australian healthcare tech giant Pro Medicus Ltd (ASX:PME) has landed a significant foothold in the U.S. market, signing a 7-year contract worth AU$40 million with radiology service provider LucidHealth. The agreement will see LucidHealth implement the Visage 7 enterprise imaging platform, delivered through a cloud-based system designed to streamline imaging services and enhance radiology workflows.
The deal, struck through Pro Medicus’ U.S. subsidiary Visage Imaging Inc, follows a transactional licensing model, with platform rollout starting immediately. LucidHealth is expected to begin its phased ‘go live’ implementation as early as the third quarter of 2025, signaling a swift transition to the new technology.
Tailored Solutions for Complex Needs
Pro Medicus CEO Dr. Sam Hupert emphasized the strategic value of the partnership, noting that LucidHealth’s diverse needs — spanning on-site, remote reading, and teleradiology services — align perfectly with the capabilities of the Visage 7 platform.
“Our proprietary server-side streaming technology is uniquely positioned to meet LucidHealth’s requirements, reinforcing Visage 7’s ability to serve not just private radiology groups, but also academic medical centers, integrated delivery networks (IDNs), and outpatient clinics,” Dr. Hupert said.
Market Reaction and Stock Performance
Pro Medicus shares traded at AU$260.99 per share, up 3.05%, at the time of writing on 3 March 2025.